Predictive Factors for Completion of TPF Induction Chemotherapy in Patients With Locally Advanced Head and Neck Cancer.
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
/ administration & dosage
Carcinoma, Squamous Cell
/ drug therapy
Cisplatin
/ administration & dosage
Disease-Free Survival
Docetaxel
/ administration & dosage
Drug-Related Side Effects and Adverse Reactions
/ classification
Female
Fluorouracil
/ administration & dosage
Head and Neck Neoplasms
/ drug therapy
Humans
Induction Chemotherapy
/ methods
Male
Middle Aged
Neoplasm Recurrence, Local
/ drug therapy
Prognosis
Head and neck cancer
cisplatin
docetaxel
fluorouracil
induction chemotherapy
Journal
Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988
Informations de publication
Date de publication:
Aug 2019
Aug 2019
Historique:
received:
03
06
2019
revised:
01
07
2019
accepted:
03
07
2019
entrez:
2
8
2019
pubmed:
2
8
2019
medline:
8
8
2019
Statut:
ppublish
Résumé
Induction therapy with docetaxel, cisplatin and fluorouracil (TPF) is a treatment option for locally advanced head and neck cancer (LAHNC), but it is not known which patients are appropriate for TPF. We retrospectively reviewed the records of patients with LAHNC who underwent induction TPF, and evaluated factors predictive of the completion of TPF treatment (defined as ≥3 cycles administered). Of the total 93 enrolled patients, 73 (78.5%) achieved therapy completion. In a multivariate analysis, hypolaryngeal/ laryngeal primary tumor site was a negative predictive factor (hazard ratio(HR)=0.32, 95% confidence interval(CI)=0.11-0.96, p=0.041) and body mass index ≥22 kg/m For patients with LAHNC, oropharyngeal primary tumor site and high body mass index can be used to predict TPF completion and may contribute to decisions on the indications for TPF in terms of safety and tolerability.
Sections du résumé
BACKGROUND
BACKGROUND
Induction therapy with docetaxel, cisplatin and fluorouracil (TPF) is a treatment option for locally advanced head and neck cancer (LAHNC), but it is not known which patients are appropriate for TPF.
PATIENTS AND METHODS
METHODS
We retrospectively reviewed the records of patients with LAHNC who underwent induction TPF, and evaluated factors predictive of the completion of TPF treatment (defined as ≥3 cycles administered).
RESULTS
RESULTS
Of the total 93 enrolled patients, 73 (78.5%) achieved therapy completion. In a multivariate analysis, hypolaryngeal/ laryngeal primary tumor site was a negative predictive factor (hazard ratio(HR)=0.32, 95% confidence interval(CI)=0.11-0.96, p=0.041) and body mass index ≥22 kg/m
CONCLUSION
CONCLUSIONS
For patients with LAHNC, oropharyngeal primary tumor site and high body mass index can be used to predict TPF completion and may contribute to decisions on the indications for TPF in terms of safety and tolerability.
Identifiants
pubmed: 31366527
pii: 39/8/4337
doi: 10.21873/anticanres.13601
doi:
Substances chimiques
Docetaxel
15H5577CQD
Cisplatin
Q20Q21Q62J
Fluorouracil
U3P01618RT
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4337-4342Informations de copyright
Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.